Document is current
Any future updates will be listed below
-
Authors
Amore, Giulia
Vacchiano, Veria
La Morgia, Chiara
Valentino, Maria L.
Caporali, Leonardo
Fiorini, Claudio
Ormanbekova, Danara
Salvi, Fabrizio
Bartoletti-Stella, Anna
Capellari, Sabina
Liguori, Rocco
Carelli, Valerio https://orcid.org/0000-0003-4923-6404
- License Information
-
More Information
Article History
Received: 13 June 2022
Revised: 24 August 2022
Accepted: 25 August 2022
First Online: 6 September 2022
Declarations
:
: CLM received consultancies fees from Chiesi Farmaceutici, Regulatory Pharma Net and Thenewway srl, speaker honoraria from Santhera Pharmaceuticals, Chiesi Farmaceutici, Regulatory Pharma Net, Thenewway srl, First Class srl and Biologix, and travel support from Santhera Pharmaceuticals. LC received speaker honoraria from First Class srl and University of Parma. RL received speaker honoraria and travel support from Amicus Therapeutics srl, Editree srl, LT3 srl, PTS srl, Planning Congressi srl, Galen Symposion srl, and participates into the advisory board of Argenx BV, Alexion Pharma Italy srl, UCB Pharma spa and Prex srl. VC received consultancies fees from Chiesi Farmaceutici and Pretzel Therapeutics and speaker honoraria from Chiesi Farmaceutici and First Class srl.
: All investigations were carried out according to the Declaration of Helsinki.
